Use of hydrophilic natural gums in formulation of sustained-release matrix tablets of tramadol hydrochloride

被引:0
作者
Jaleh Varshosaz
Naser Tavakoli
Fatemeh Kheirolahi
机构
[1] Isfahan University of Medical Sciences,Department of Pharmaceutics, School of Pharmacy
来源
AAPS PharmSciTech | / 7卷
关键词
natural gums; xanthan; guar gum; tramadol; sustained-release;
D O I
暂无
中图分类号
学科分类号
摘要
The objective of this work was to develop matrix sustained-release tablets of highly water-soluble tramadol HCl using natural gums (xanthan [X gum] and guar [G gum]) as cost-effective, nontoxic, easily available, and suitable hydrophilic matrix systems compared with the extensively investigated hydrophilic matrices (ie, hydroxypropyl methylcellulose [HPMC]/carboxymethyl cellulose [CMC] with respect to in vitro drug release rate) and hydration rate of the polymers. Matrix tablets of tramadol (dose 100 mg) were produced by direct compression method. Different ratios, of 100∶0, 80∶20, 60∶40, 20∶80, 0∶100 of G gum (or X):HPMC, X gum:G gum, and triple mixture of these polymers (G gum, X gum, HPMC) were applied. After evaluation of physical characteristics of tablets, the dissolution test was, performed in the phosphate buffer media (pH 7.4) up to 8 hours. Tablets with only X had the highest mean dissolution time (MDT), the least dissolution efficiency (DE8%), and released the drug following a zero-order model via swelling, diffusion, and erosion mechanisms. Guar gum alone could not efficiently control the drug release, while X and all combinations of natural gums with HPMC could retard tramadol HCl release. However, according to the similarity factor (f2), pure HPMC and H8G2 were the most similar formulations to Topalgic-LP as the reference standard.
引用
收藏
相关论文
共 88 条
[1]  
Altman RA(2000)Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update Arthritis Rheum. 43 1905-1915
[2]  
Hochberg MC(2004)Clinical pharmacology of tramadol Clin Pharmacokinet. 43 879-923
[3]  
Moskowitz RW(1999)Analgesic efficacy and tolerability of tramadol 100 mg sustained release capsules in patients with moderate to severe chronic low back pain Clin Drug Invest. 17 415-423
[4]  
Schnitzer TJ(2005)Long-term tolerability of tramadol LP, a new once-daily formulation, in patients with osteoarthritis or low back pain J Clin Pharm Ther. 30 113-120
[5]  
Grond S(2004)Efficacy and tolerability of sustained-release tramadol in the treatment of symptomatic osteoarthritis of the hip or knee: a multicenter, randomized, double-blind, placebo-controlled study Clin Ther. 26 1774-1782
[6]  
Sablotzki A(2004)Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee J Pain Symptom Manage. 28 59-71
[7]  
Raber M(2003)Controlled release formulation of tramadol hydrochloride using hydrophilic and hydrophobic matrix system AAPS PharmSciTech. 4 E31-E31
[8]  
Hoffman S(2001)Controlled release of tramadol hydrochloride from matrices prepared using glyceryl behenate Eur J Pharm Biopharm. 52 231-235
[9]  
Junge K(2000)In vitro/in vivo characterization of a tramadol HCl depot system composed of monoolein and water Biol Pharm Bull. 23 627-631
[10]  
Momberger H(2000)Microencapsulation and characterization of tramadol-resin complexes J Control Release. 66 107-113